[The prognosis of ovarian cancer depends on the CA125 value at the end of induction therapy]
other
public-domain-us
AI-generated summary
Ovarian cancer patients with CA125 levels below 35 units/ml after induction therapy survived significantly longer than those with levels above 35 units/ml.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The prognosis of ovarian cancer depends on the CA125 value at the end of induction therapy. The relationship between the prognosis and the CA125 value at the end of induction therapy was analysed in 16 ovarian cancers. In the group with a CA125 value less than 35 units/ml after the induction therapy (initial surgery + 3 courses of chemotherapy) all patients have survived for 18-45 months since the initial treatment to the present, whereas in the group with a CA125 value above 35 units/ml all patients died within 16 months after the initial treatment. Comparison of the survival rates in these two groups showed a significant difference. These results suggest that the most important factor that affects prognosis in patients with ovarian cancer is the normalization of the CA125 value after the induction therapy.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- pubmed
- last seen: 2026-05-13T22:12:00.397535+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine